60200 Federal Register / Vol. 65, No. 196 / Tuesday, October 10, 2000 / Notices

NOTIFICATION REQUIREMENTS—Continued

Number of respondents

Number of

transactions per

respondent

Total transactions

Time per

response

(hours)

Total burden

hours

20,639 Borrowers ...................................................................................... 1 20,639 0.2 3,440

Total Notification ................................................................................. .......................... .......................... ........................ 51,721

RECORDKEEPING REQUIREMENTS

Number of respondents

Number of

transactions per

respondent

Total transactions

Time per

response

(hours)

Total burden

hours

22 Lenders ................................................................................................. 4,929 128,169 0.2 28,993

200 Schools ............................................................................................... 768 101,639 0.1 14,437

Total Recordkeeping .......................................................................... .......................... .......................... ........................ 43,430

Total Annual Burden: 95,290 Hrs.

Written comments and

recommendations concerning the

proposed information collection should

be sent within 30 days of this notice to:

John Morrall, Human Resources and

Housing Branch, Office of Management

and Budget, New Executive Office

Building, Room 10235, Washington, DC

20503.

Dated: October 2, 2000.

Jane Harrison,

Director, Division of Policy Review and

Coordination.

[FR Doc. 00–25812 Filed 10–6–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Availability for Licensing: Chromatin

Insulator Protecting Expressed Genes

of Interest for Human Gene Therapy or

Other Mammalian Transgenic Systems

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The National Institutes of

Health (NIH), Department of Health and

Human Services (DHHS), seeks

licensee(s) who can effectively pursue

the preclinical, clinical and commercial

development of the technology

embodied in U.S. Patent 5,610,053

entitled ‘‘DNA Sequence Which Acts as

a Chromatin Insulator Element to

Protect Expressed Genes from Cis-acting

Regulatory Sequences in Mammalian

Cells,’’ issued on March 11, 1997. The

invention describes the isolation,

identification, and characterization of a

DNA element residing in higher

eukaryotic chromatin structural

domains. All fields of use are available

for licensing. The patent rights in this

technology have been assigned to the

United States of America.

ADDRESSES: Requests for copies of the

issued patent, inquiries, comments and

other materials relating to the

contemplated licenses should be

directed to: Girish C. Barua, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, Maryland 20852–

3804; telephone: 301/496–7735 ext. 266;

Facsimile: 301/402–0220; E-mail:

baruag@od.nih.gov.

SUPPLEMENTARY INFORMATION: The

technology provides the isolation of a

functional DNA sequence comprising a

chromatin insulating element from a

vertebrate system and provides the first

employment of the pure insulator

element as a functional insulator in

mammalian cells. The technology

further relates to a method for insulating

the expression of a gene from the

activity of cis-acting regulatory

sequences in eukaryotic chromatin.

This technology could be of major

importance in providing a mechanism

and a tool to restrict the action of cisacting regulatory elements on genes

whose activities or encoded products

are needed or desired to be expressed in

mammalian transgenic systems. This

technology provides the first pure

insulator element to function solely as

an insulator element in human cells.

Accordingly, this technology could have

tremendous practical implications for

transgenic technology and human gene

therapies, either in vitro or in vivo.

The technology further provides a

method and constructs for insulating the

expression of a gene or genes in

transgenic animals such that the

transfected genes will be protected and

stably expressed in the tissues of the

transgenic animal or its offspring. For

example, even if the DNA of the

construct integrates into areas of silent

chromatin in the genomic DNA of the

host animal, the gene will continue to

be expressed. The invention could

provide a means of improving the stable

integration and expression of any

transgenic construct of interest, with

efficiencies higher than are achieved

presently. Use of this invention may

represent a large potential savings for

licensee’s constructing transgenic cell

lines or animals.

The NIH seeks licensee(s), who in

accordance with requirements and

regulations governing the licensing of

government-owned inventions (37 CFR

part 404), have meritorious plan(s) for

the development of the DNA Chromatin

Insulator technology to a marketable

status to meet the needs of the public.

Dated: September 29, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 00–25893 Filed 10–6–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Office of the Director, National

Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Director’s Council of Public

Representatives.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

Federal Register / Vol. 65, No. 196 / Tuesday, October 10, 2000 / Notices 60201

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: Director’s Council of

Public Representatives.

Date: October 31-November 1, 2000.

Time: October 31, 2000, 8:30 am to 3:30

pm.

Agenda: Among the topics proposed for

discussion are: (1) human research

protections; (2) informed consent; and (3)

medical applications research.

Place: National Institutes of Health, 9000

Rockville Pike, Building 31C, Conference

Room 6, Bethesda, MD 20892.

Time: November 1, 2000, 8 am to 10 am.

Agenda: Same as above.

Place: National Institutes of Health, 9000

Rockville Pike, Building 31C, Conference

Room 6, Bethesda, MD 20892.

Contact Person: Jennifer E. Gorman, Public

Liaison/COPR Coordinator, Office of

Communications and Public Liaison, Office

of the Director, National Institutes of Health,

9000 Rockville Pike, Building 1, Room 344,

Bethesda, MD 20892, (301) 435–4448.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.14, Intramural Research

Training Award; 93.187, Undergraduate

Scholarship Program for Individuals from

Disadvantaged Backgrounds; 93.22, Clinical

Research Loan Repayment Program for

Individuals from Disadvantaged

Backgrounds; 93.232, Loan Repayment

Program for Research Generally; 93.39,

Academic Research Enhancement Award;

93.936, NIH Acquired Immunodeficiency

Syndrome Research Loan Repayment

Program, National Institutes of Health, HHS)

Dated: October 3, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–25878 Filed 10–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Research

Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(a)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Research Resources Special Emphasis Panel,

Comparative Medicine.

Date: October 20, 2000.

Time: 3 p.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: Office of Review, National Center for

Research Resources, 6705 Rockledge Drive,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Sybil A. Wellstood,

Scientific Review Administrator, Office of

Review, National Center for Research

Resources, 6705 Rockledge Drive, MSC 7965,

Room 6018, Bethesda, MD 20892–7965, 301–

435–0814.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333;

93.371, Biomedical Technology; 93.389,

Research Infrastructure, National Institutes of

Health, HHS)

Dated: September 29, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–25886 Filed 10–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Research

Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Research Resources Special Emphasis Panel

Comparative Medicine.

Date: October 12, 2000.

Time: 3:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: Office of Review, National Center for

Research Resources, 6705 Rockledge Drive,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Sybil A. Wellstood,

Scientific Review Administrator, Office of

Review, National Center for Research

Resources, 6705 Rockledge Drive, MSC 7965,

Room 6018, Bethesda, MD 20892–7965; 301–

435–0814.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333;

93.371, Biomedical Technology; 93.389,

Research Infrastructure, National Institutes of

Health, HHS)

Dated: September 29, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–25887 Filed 10–6–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel,

Demonstration and Education Research

Applications (R18s).

Date: November 2, 2000.

Time: 9 a.m. to 4:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: Hilton National Airport Hotel, 2399

Jefferson Davis Highway, Arlington, VA

22202.

Contact Person: Louise P. Corman,

Scientific Review Administrator, Review

Branch, Room 7180, Division of Extramural

Affairs, National Heart, Lung, and Blood

Institute, National Institutes of Health,

Bethesda, MD 20892.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and